Rethinking anti-cancer drug discovery: the evolution from polypharmacy to unified drug units
Abstract
Despite advances in current anti-cancer therapies, challenges such as drug resistance, toxicity, and tumor heterogeneity persist. The limitations of traditional single-target drugs and simple combination therapies are becoming increasingly apparent[1][1]. To address these issues, a novel treatment
Fields of Study & Subjects
Protein Degradation and Inhibitors
Cancer
Stress
Anesthesia
and Immune Response
PARP inhibition in cancer therapy
Publication details
- Journal / source
- Cancer Biology and Medicine
- Publisher
- China Anti-cancer Association
- Volume
- 23
- Issue
- 1
- Pages
- 1–6
- Publication date
- 29 January 2026
- Language
- EN